Annual report 2018

26 | Galenica annual report 2018 More efficient processes, new products Pre-wholesaler Alloga put a third cold room into operation in Burgdorf in 2018, expanding internal capacity for the refrigerated storage of medications by one third. Alloga also made its transport logistics more efficient with regard to vaccines in the year under review: While vaccines were previously transported on pallets in cool boxes, an uninter- rupted chain in temperature-controlled lorries is now avail- able. This means that larger quantities of vaccines can be transported in shorter times, thereby ensuring better avail- ability of the vaccines during the flu season. In addition, Alloga attracted further well-known pharma partners as new customers and gained major hospitals for the introduction of electronic invoicing in 2018, while also pressing ahead with the ongoing “Modulo” project to switch to SAP’s new enterprise resource planning (ERP) system. The photovoltaic system on the roof of the Alloga building in Burgdorf was completed as planned in November 2018. Providing an average of one megawatt of electricity, it not only generates electricity for the company’s own use, but in summer, shade provided by the solar panels will reduce energy consumption for cooling the building. With a surface area of some 10,000 m 2 , it is one of the largest systems in the region and quintuples the production capacity of opera- tor Solarstadt Burgdorf Ltd. New own brand from Galexis Despite the challenging market environment, Galexis was also able to gain new partners, including Japanese company Shiseido, which produces cosmetics for the specialist retail trade, and is now banking on Galexis’ efficiency and expertise to handle inventory management, shipment preparation and dispatch for Switzerland. Galexis also commissioned a new, optimised cool box that guarantees the required tempera- ture of transported goods for 30 hours. Galexis is thereby contributing further to drug safety and has at the same time taken a leading role in the transport of modern medicines that must be stored in cool conditions. These products are produced using biotechnology and represent a fast-growing market segment (biologicals). Services Business sector Strategic priorities – Reinforce customer competitiveness with high-quality services and innovative, tailored offerings. – Bundle the competences as a pre-wholesaler and wholesaler for customers and suppliers. – Develop trend-setting E-Health offerings for the Swiss healthcare market. – Improve efficiency by further optimising processes. – Promote growth: organically and with expansion of the customer portfolio through pharmacies and physicians, and by resuming direct deliveries from the manufacturer. Services